Publications
Detailed Information
CSF total tau/α-synuclein ratio improved the diagnostic performance for Alzheimers disease as an indicator of tau phosphorylation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shim, Kyu H | - |
dc.contributor.author | Kang, Min J | - |
dc.contributor.author | Suh, Jee W | - |
dc.contributor.author | Pyun, Jung-Min | - |
dc.contributor.author | Ryoo, Nayoung | - |
dc.contributor.author | Park, Young H | - |
dc.contributor.author | Youn, Young C | - |
dc.contributor.author | Jang, Jae-Won | - |
dc.contributor.author | Jeong, Jee H | - |
dc.contributor.author | Park, Kyung W | - |
dc.contributor.author | Choi, Seong H | - |
dc.contributor.author | Suk, Kyoungho | - |
dc.contributor.author | Lee, Ho-Won | - |
dc.contributor.author | Ko, Pan-Woo | - |
dc.contributor.author | Lee, Chan-Nyoung | - |
dc.contributor.author | Lim, Tae-Sung | - |
dc.contributor.author | An, Seong S A | - |
dc.contributor.author | Kim, SangYun | - |
dc.date.accessioned | 2020-09-09T05:26:58Z | - |
dc.date.available | 2020-09-09T05:26:58Z | - |
dc.date.issued | 2020-07-13 | - |
dc.identifier.citation | Alzheimer's Research & Therapy. 2020 Jul 13;12(1):83 | - |
dc.identifier.uri | https://doi.org/10.1186/s13195-020-00648-9 | - |
dc.identifier.uri | https://hdl.handle.net/10371/168847 | - |
dc.description.abstract | Abstract
Background Recently, several studies suggested potential involvements of α-synuclein in Alzheimers disease (AD) pathophysiology. Higher concentrations of α-synuclein were reported in cerebrospinal fluid (CSF) of AD patients with a positive correlation towards CSF tau, indicating its possible role in AD. We analyzed the CSF biomarkers to verify whether α-synuclein could be an additional supported biomarker in AD diagnosis. Methods In this cross-sectional study, CSF samples of 71 early-onset AD, 34 late-onset AD, 11 mild cognitive impairment, 17 subjective cognitive decline, 45 Parkinsons disease, and 32 healthy control (HC) were collected. CSF amyloid-β1-42 (A), total tau (N), and phosphorylated tau181 (T) were measured by commercial ELISA kits, and in-house ELISA kit was developed to quantify α-synuclein. The cognitive assessments and amyloid-PET imaging were also performed. Results CSF α-synuclein manifested a tendency to increase in AD and to decreased in Parkinsons disease compared to HC. The equilibrium states of total tau and α-synuclein concentrations were changed significantly in AD, and the ratio of total tau/α-synuclein (N/αS) was dramatically increased in AD than HC. Remarkably, N/αS revealed a strong positive correlation with tau phosphorylation rate. Also, the combination of N/αS with amyloid-β1-42/phosphorylated tau181ratio had the best diagnosis performance (AUC = 0.956, sensitivity = 96%, specificity = 87%). In concordance analysis, N/αS showed the higher diagnostic agreement with amyloid-β1-42 and amyloid-PET. Analysis of biomarker profiling with N/αS had distinctive characteristics and clustering of each group. Especially, among the group of suspected non-Alzheimers disease pathophysiology, all A−T+N+ patients with N/αS+ were reintegrated into AD. Conclusions The high correlation of α-synuclein with tau and the elevated N/αS in AD supported the involvement of α-synuclein in AD pathophysiology. Importantly, N/αS improved the diagnostic performance, confirming the needs of incorporating α-synuclein as a biomarker for neurodegenerative disorders. The incorporation of a biomarker group [N/αS] could contribute to provide better understanding and diagnosis of neurodegenerative disorders. | - |
dc.title | CSF total tau/α-synuclein ratio improved the diagnostic performance for Alzheimers disease as an indicator of tau phosphorylation | - |
dc.type | Journal Article | - |
dc.language.rfc3066 | en | - |
dc.rights.holder | The Author(s) | - |
dc.date.updated | 2020-07-19T03:47:18Z | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.